COFEPRIS Challenges 2020

By

Since December 1st, 2018 a historical change in administration that consisted of a new president who is committed to Public Office cleansing of corrupt and unequal practices had a strong impact on the whole country course of operation. Many institutions were eliminated or were audited and restructured. 

Cofepris was audited and analyzed for permanence or removal but was decided to stay active. This, however, caused a complete pause in real operation for almost a whole Quarter of the year; therefore in between 2019-2020, we observed a complete change in staff and certain evaluation criteria.

The main changes to this day include grouping criteria, better answering time for traditional track processes versus previous years and a tendency to avoid any preferential treatment tracks (like Third Authorized Party processes).

Despite initial setbacks, right now answering times are becoming much better than in any previous years which becomes a strong solution given by this administration.

-Copyright 2020 Medisi America. Replication and quote of this content are subject to International Author Law.

Posted in News.
Share

Deja una respuesta

Tu dirección de correo electrónico no será publicada.

Related Posts

  •
    18 junio, 2019

    More than 1 million Class I medical device units recalled in Q1

    For the third consecutive quarter, more than one million Class I units were recalled during 2019’s Q1. If you want to read more about this news click here. If you want to read more about this news click here.

  •
    10 octubre, 2019

    Deep brain stimulation can be effective for severe depression

    Researchers who monitored people with deep brain stimulation implants for 8 years suggest that the treatment can benefit those with severe depression. Regulators in the United States have already approved deep brain stimulation for the treatment of Parkinson’s disease, epilepsy, essential tremor, and obsessive-compulsive disorder. The treatment involves implanting wires into the brain and a stimulator in the chest …

  •
    10 octubre, 2019

    Medtronic announces Infuse spine trial

    Medtronic (NYSE:MDT) said today that it won FDA approval for a clinical trial of its Infuse bone graft in transforaminal lumbar interbody fusion spine procedures. The Minneapolis-based company started recruiting for the prospective, randomized pivotal trial, which is slated to enroll up to 1,000 patients. The TLIF trial would be the second clinical trial for Infuse, …

  •
    18 junio, 2019

    New York Times calls for tightened medical device regulation from FDA

    The New York Times last Friday released an editorial calling for improved regulation on medical devices from the FDA, citing a number of recent controversial devices that have made headlines for injuries and deaths related to their use.  If you want to read more about this news click here.